In the past few years, an entirely new approach to the treatment of inflammatory bowel disease, the novel small molecules, have emerged from the laboratory and are now available to treat patients with IBD. This session will concentrate on the "need to know" information for patient selection and treatment with two different families of small molecules: 1) the JAK inhibitors and 2) the S1P modulators. These oral therapies are predicted to grow in popularity amongst patients and providers and become mainstays in the treatment of ulcerative colitis, and eventually Crohn's disease.
Learning Objectives:
1. Indentify the currently available janus kinase (JAK) inhibitors for the treatment of moderate to severe ulcerative colitis.
2. Indentify the currently available S1P modulator for the treatment of moderate to severe ulcerative colitis.
3. Understand the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators